Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which compr… Read more
Market Cap & Net Worth: Xilio Development Inc (XLO)
Xilio Development Inc (NASDAQ:XLO) has a market capitalization of $501.83 Million ($501.83 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22665 globally and #7995 in its home market, demonstrating a 1275.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xilio Development Inc's stock price $7.43 by its total outstanding shares 67540930 (67.54 Million).
Xilio Development Inc Market Cap History: 2021 to 2026
Xilio Development Inc's market capitalization history from 2021 to 2026. Data shows change from $1.08 Billion to $501.83 Million (-15.99% CAGR).
Index Memberships
Xilio Development Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #606 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2007 of 3165 |
Weight: Xilio Development Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Xilio Development Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xilio Development Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.17x
Xilio Development Inc's market cap is 10.17 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $64.50 Million | $6.34 Million | -$58.24 Million | 10.17x | N/A |
Competitor Companies of XLO by Market Capitalization
Companies near Xilio Development Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Xilio Development Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Xilio Development Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Xilio Development Inc's market cap moved from $1.08 Billion to $ 501.83 Million, with a yearly change of -15.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $501.83 Million | +1060.57% |
| 2025 | $43.24 Million | -32.96% |
| 2024 | $64.50 Million | +73.64% |
| 2023 | $37.15 Million | -79.55% |
| 2022 | $181.69 Million | -83.19% |
| 2021 | $1.08 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Xilio Development Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $501.83 Million USD |
| MoneyControl | $501.83 Million USD |
| MarketWatch | $501.83 Million USD |
| marketcap.company | $501.83 Million USD |
| Reuters | $501.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.